WAKEFIELD, Mass.--(BUSINESS WIRE)--Nov. 9, 2005--Implant Sciences Corporation (AMEX: "IMX", "IMX.WS") a developer and manufacturer of products for national security, medicine and industry, today announced the timely shipment of a significant number of units of our Quantum Sniffer(TM) handheld explosives detection equipment ordered for use in China. This first shipment was made pursuant to the requirements of the order received by the China Railway Administration for an initial quantity of 101 units. Due to competitive reasons, the Company chooses not to disclose the quantity of units shipped. As part of our requirement for shipment, we have received the balance of the payment due on these units and we have received the export license from the U.S. Department of Commerce. The remainder of the 101 units is expected to ship before the end of this quarter. Another 22 units for various law enforcement agencies in China are expected to be shipped in January.
The Company's Quantum Sniffer explosives detection equipment has now been shipped for use in countries that include China, Greece, Pakistan, Italy, South Korea, Kuwait, Dubai, United Arab Emirates, Australia, UK, and US. The Quantum Sniffer was developed for use in the detection of trace residues of explosives materials for aviation and transportation security, protection of high threat facilities, infrastructure, customs and border protection, and cargo screening.
Erik Bates, Vice President, Operations - Explosives Detection Division, stated, "Over the past year we have built a manufacturing facility capable of producing commercial quantities of our Quantum Sniffer explosives detection equipment. Key to our production capabilities was the assembly of a production team with the expertise to transform technology developed by scientists into a commercial product that could be produced in a cost-effective manner while meeting customer specifications and delivery requirements. This first shipment to China represents the culmination of our successful efforts in building a first class manufacturing team and facility."
Dr. Anthony J. Armini, PhD., CEO of Implant Sciences, commented, "Over the past year and a half, Implant has successfully transformed its explosives detection business from a development stage business to a commercial business capable of marketing, distributing, manufacturing and servicing its Quantum Sniffer product line. We have put in place a manufacturing facility capable of producing reliable explosives detection equipment in accordance with customer specifications and delivery requirements. In addition, our sales and manufacturing team have collaborated in navigating through the regulatory waters to obtain the export licenses necessary to complete the process of timely product delivery. We currently have outstanding quotations for approximately $15 million of our Quantum Sniffer explosives detection equipment. Although there can be no assurance that these quotations will result in firm orders, we are optimistic that fiscal 2006 will be one of great promise with respect of the growth of sales for our explosives detection business unit."
About Implant Sciences
Implant Sciences, incorporated in 1984, is using its core ion technology to develop, manufacture and market products for the homeland security, semiconductor and medical device industries. The Company has developed and commercialized portable and bench-top detection devices to identify explosives which are distributed under the Quantum Sniffer(TM) brand name. The Company also provides state of the art ion implantation and wafer analytical services for the semiconductor industry. The Company also develops, manufactures and sells radioactive products for the treatment of cancer, including sales of radioactive seeds for the treatment of prostate cancer and development of a new, FDA approved radioactive source for use in the treatment of breast cancer. For further details on the Company and its products please visit the Company's website at www.implantsciences.com.
Implant Sciences believes that this release contains forward-looking statements that are subject to risks and uncertainties. Such statements are based on management's current expectations and are subject to facts that could cause results to differ materially from the forward-looking statements. For further information you are encouraged to review Implant Sciences' filings with the Securities and Exchange Commission.
CONTACT: Implant Sciences Corporation Investor Relations (781) 246-0700, ext. 105 www.implantsciences.com KEYWORD: MASSACHUSETTSINDUSTRY KEYWORD: MANUFACTURING PHARMACEUTICAL MEDICAL DEVICES AIRLINES TRANSPORTATION HARDWARE LEGAL/LAW AEROSPACE/DEFENSE GOVERNMENT PRODUCTSOURCE: Implant Sciences Corporation
